vs
Embecta Corp.（EMBC）与FTAI Infrastructure Inc.（FIP）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是FTAI Infrastructure Inc.的1.4倍（$261.2M vs $188.4M），Embecta Corp.净利率更高（16.9% vs -79.7%，领先96.6%），FTAI Infrastructure Inc.同比增速更快（95.9% vs -0.3%），过去两年FTAI Infrastructure Inc.的营收复合增速更高（49.0% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
FTAI基础设施有限公司持有、运营并投资交通物流、中游能源、发电等核心领域的优质关键基础设施资产，主要面向北美市场，聚焦拥有稳定长期现金流、合同约定收入流的项目，为利益相关方创造可持续回报。
EMBC vs FIP — 直观对比
营收规模更大
EMBC
是对方的1.4倍
$188.4M
营收增速更快
FIP
高出96.2%
-0.3%
净利率更高
EMBC
高出96.6%
-79.7%
两年增速更快
FIP
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $188.4M |
| 净利润 | $44.1M | $-150.2M |
| 毛利率 | 61.9% | — |
| 营业利润率 | 31.9% | — |
| 净利率 | 16.9% | -79.7% |
| 营收同比 | -0.3% | 95.9% |
| 净利润同比 | — | -387.6% |
| 每股收益（稀释后） | $0.74 | $-1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCFIP
| Q1 26 | — | $188.4M | ||
| Q4 25 | $261.2M | $143.5M | ||
| Q3 25 | $264.0M | $140.6M | ||
| Q2 25 | $295.5M | $122.3M | ||
| Q1 25 | $259.0M | $96.2M | ||
| Q4 24 | $261.9M | $80.8M | ||
| Q3 24 | $286.1M | $83.3M | ||
| Q2 24 | $272.5M | $84.9M |
净利润EMBCFIP
| Q1 26 | — | $-150.2M | ||
| Q4 25 | $44.1M | $-97.7M | ||
| Q3 25 | $26.4M | $-104.5M | ||
| Q2 25 | $45.5M | $-70.0M | ||
| Q1 25 | $23.5M | $120.2M | ||
| Q4 24 | $0 | $-124.7M | ||
| Q3 24 | $14.6M | $-43.0M | ||
| Q2 24 | $14.7M | $-48.1M |
毛利率EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | 31.9% | -45.7% | ||
| Q3 25 | 21.4% | -70.8% | ||
| Q2 25 | 31.8% | -56.4% | ||
| Q1 25 | 24.3% | 81.8% | ||
| Q4 24 | 11.0% | -152.7% | ||
| Q3 24 | 9.2% | -51.7% | ||
| Q2 24 | 20.5% | -56.4% |
净利率EMBCFIP
| Q1 26 | — | -79.7% | ||
| Q4 25 | 16.9% | -68.1% | ||
| Q3 25 | 10.0% | -74.4% | ||
| Q2 25 | 15.4% | -57.2% | ||
| Q1 25 | 9.1% | 125.0% | ||
| Q4 24 | — | -154.4% | ||
| Q3 24 | 5.1% | -51.6% | ||
| Q2 24 | 5.4% | -56.7% |
每股收益（稀释后）EMBCFIP
| Q1 26 | — | $-1.32 | ||
| Q4 25 | $0.74 | $-1.04 | ||
| Q3 25 | $0.44 | $-1.38 | ||
| Q2 25 | $0.78 | $-0.73 | ||
| Q1 25 | $0.40 | $0.89 | ||
| Q4 24 | $0.00 | $-1.21 | ||
| Q3 24 | $0.24 | $-0.45 | ||
| Q2 24 | $0.25 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $37.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $-122.5K |
| 总资产 | $1.1B | $5.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCFIP
| Q1 26 | — | $37.9M | ||
| Q4 25 | $201.3M | $57.4M | ||
| Q3 25 | $225.5M | $34.7M | ||
| Q2 25 | $230.6M | $33.6M | ||
| Q1 25 | $209.3M | $26.3M | ||
| Q4 24 | $210.0M | $27.8M | ||
| Q3 24 | $267.5M | $20.3M | ||
| Q2 24 | $275.1M | $33.1M |
总债务EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | — | $3.8B | ||
| Q3 25 | $1.4B | $3.7B | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | — | $1.6B |
股东权益EMBCFIP
| Q1 26 | — | $-122.5K | ||
| Q4 25 | $-613.1M | $21.3M | ||
| Q3 25 | $-650.6M | $181.1M | ||
| Q2 25 | $-669.6M | $375.5M | ||
| Q1 25 | $-736.2M | $476.2M | ||
| Q4 24 | $-768.8M | $202.7M | ||
| Q3 24 | $-738.3M | $370.8M | ||
| Q2 24 | $-763.7M | $394.8M |
总资产EMBCFIP
| Q1 26 | — | $5.7B | ||
| Q4 25 | $1.1B | $5.7B | ||
| Q3 25 | $1.1B | $5.5B | ||
| Q2 25 | $1.2B | $4.4B | ||
| Q1 25 | $1.1B | $4.1B | ||
| Q4 24 | $1.1B | $2.4B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.3B | $2.5B |
负债/权益比EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | — | 176.99× | ||
| Q3 25 | — | 20.59× | ||
| Q2 25 | — | 8.21× | ||
| Q1 25 | — | 5.79× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 4.14× | ||
| Q2 24 | — | 3.94× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $-69.4M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCFIP
| Q1 26 | — | $-69.4M | ||
| Q4 25 | $17.2M | $-2.8M | ||
| Q3 25 | $84.0M | $-24.4M | ||
| Q2 25 | $81.2M | $-5.2M | ||
| Q1 25 | $31.8M | $-85.7M | ||
| Q4 24 | $-5.3M | $-8.1M | ||
| Q3 24 | $26.6M | $14.2M | ||
| Q2 24 | $-2.1M | $-17.6M |
自由现金流EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | $16.6M | $-68.6M | ||
| Q3 25 | $76.7M | $-90.7M | ||
| Q2 25 | $80.8M | $-87.5M | ||
| Q1 25 | $31.7M | $-151.7M | ||
| Q4 24 | $-6.8M | $-34.3M | ||
| Q3 24 | — | $-11.7M | ||
| Q2 24 | $-11.8M | $-32.1M |
自由现金流率EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | -47.8% | ||
| Q3 25 | 29.1% | -64.5% | ||
| Q2 25 | 27.3% | -71.6% | ||
| Q1 25 | 12.2% | -157.7% | ||
| Q4 24 | -2.6% | -42.4% | ||
| Q3 24 | — | -14.0% | ||
| Q2 24 | -4.3% | -37.9% |
资本支出强度EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 45.9% | ||
| Q3 25 | 2.8% | 47.2% | ||
| Q2 25 | 0.1% | 67.3% | ||
| Q1 25 | 0.0% | 68.6% | ||
| Q4 24 | 0.6% | 32.5% | ||
| Q3 24 | 0.0% | 31.1% | ||
| Q2 24 | 3.6% | 17.2% |
现金转化率EMBCFIP
| Q1 26 | — | — | ||
| Q4 25 | 0.39× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | -0.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
FIP
暂无分部数据
